Background
and EUR-350G sublineages, which were both associated with a substantial absolute risk (>50%) of CIN3+. 
Conclusions

Materials and Methods
Cohort
The population-based cohort has been previously described in detail 17 . E6 PCR products were sequenced by the fluorescent dye dideoxy termination method using an ABI Prism 377 DNA sequencer (PE Applied Biosystems). For the sequencing reaction, the same primers were used as for the PCR reaction.
The sequences were determined for both strands.
Statistical analysis
Study women were classified into three exclusive groups based upon the outcome of their HPV16 infection both at the second examination and during passive follow-up; (i) clearance, including all women who became HPV16
negative at the second examination, (ii) persistence no CIN3+, defined as women who remained HPV16 positive at the second examination, but who did not develop CIN3+, and (iii) persistence CIN3+, defined as women who remained HPV16 positive at the second examination and who developed CIN3+. Of note, 18 CIN3+ cases arose in women with cleared HPV16 infection (8 EUR-350T and 10 EUR-350G), but these CIN3+ cases were not studied separately due to the lack of data on the HPV type present in the CIN3+ biopsy.
The relative risks of clearance, persistence, and progression were compared between different HPV16 E6 polymorphisms and lineages, using crude odds ratios (OR) and corresponding 95% confidence intervals (CI).
Results
Of the 261 HPV16-positive women with normal cytology at baseline, 199
cleared their infection and 62 persisted. Among the women with persistent infections, 32 (51.6%) developed CIN3+ during the ~11-year follow-up period (Table 1) . 
Discussion
We report the first prospective study showing significant differences in natural history between the HPV16 variant lineages that predominate in Europe. This adds to the evidence from previous cohort studies showing that non-EUR HPV16 variants are more likely to persist and progress to CIN3+ than EUR HPV16 variants 28, 32, 35 . Our findings suggest that there is additional stratification of risk within the HPV16 EUR lineage so that, among Danish women at least, variants containing 350T (including the HPV16 prototype) have a higher risk of persistence and progression to CIN3+ than those containing 350G.
HPV16 infections circulating in the general Danish population were
shown to be predominantly of the EUR variant lineage (97%), as seen in a previous population-based cohort study in France (95%) 11 and among series of , no statistically significant differences in risk for HPV16 persistence were identified by variant status. However, the definition of HPV16 persistence was less well defined than in the present study (i.e., persistent at 2 years) and 95% confidence intervals remain compatible with the present findings. EUR-350T accounted for 62% of all EUR lineages at baseline in Denmark, which compares with 52% in the French study 11 and with 45% among European women with normal cytology included in a recent literature review of cross-sectional studies 31 .
Of note, the increased risk for CIN3+ associated with EUR-350T
variants in the present study, although of borderline statistical significance, seemed to be primarily explained by the increased risk of persistence per se, with no evidence of additional excess risk of progression to CIN3 given persistent infection. This is similar to what has been reported for the differences in persistence and CIN3+ risk observed between non-EUR and EUR HPV16
variants in a previous cohort study 28 .
Genetic variations in HPV16 may influence the prognosis of an infection in two ways, either by differing in their functional abilities or by evading the host's immune system. Given the fact that the increased risk seems stronger for persistence, rather than for progression to CIN3 given a persistent infection, the second option seems more likely. It is possible that HPV16 variants in concert with HLA 4 and other immune-genetic polymorphisms play a role in persistence. , whereas most have shown no significant differences in their relative distribution 14, 15, 20, 30, 38 or even suggest that the potential carcinogenicity of EUR-350T versus EUR-350G might be population-dependent 37 .
If differences by population are confirmed to exist, they might be explained by residual genetic heterogeneity within HPV16 genomes classified solely upon position 350. Indeed, although the 350-position is highly polymorphic, it does not seems to robustly define phylogenetic lineages 8 .
Alternatively, the oncogenicity of HPV16 variants also seem to differ by the ethnic origin of the host 34, 35 , suggesting the possibility of host variant interaction effects. Larger case-control studies with appropriate population-based controls are warranted in this regard.
The strengths of the present study include the population-based sample and the assessment of CIN3+ status over a long period of follow-up that had minimal scope to be biased by HPV variant status at study entry 17 . The principle limitation was the inability to make any robust reflection on the potentially increased carcinogenicity of non-EUR HPV16 lineages 32, 35, 28 , due to their rarity in the Danish population. However, the fact that two out of the seven women infected with HPV16 of non-EUR lineages at baseline developed CIN3+ (14%), is consistent with an elevated risk for these variants 2, 12 .
Among HPV16 infections that were persistent at 2 years, both EUR-350T and EUR-350G variants were associated with at least 50% risk of CIN3+ within 11 years, as reported previously for all HPV16-positive women in this cohort 17 . This compares with a figure of 18% for all non-HPV16 HR types in the same study (Figure 1 ). Indeed, a previous cohort study in France showed that both EUR-350T and EUR-350G variants were at increased risk of progression to CIN2/3 in comparison with all HR types other than HPV16
11
. Thus, although the present study provides evidence that there are differences among the EUR HPV16 lineage in persistence, it also shows that both EUR-350T and EUR-350G are associated with a substantial absolute risk of progression to CIN3+.
Taking this evidence together with the fact that both lineages are found commonly in cervical cancers in Northern Europe 3, [13] [14] [15] 20, 36, 37 , means that any clinical utility of variant analysis is not yet evident. Nevertheless, understanding the genetic basis of differences in the carcinogenicity of HPV16 variants, which may be driven by related sequence differences in other parts of the HPV16 genome, may help us unravel important biological and/or immunological interactions between virus and host that would lead to better tools to control HPV infection and its malignant consequences.
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